Blocked cellular differentiation is a central pathologic feature of the myeloid malignancies,
myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Treatment regimens …

Myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal hematopoietic
stem cell disorders characterized by myeloid dysplasia, peripheral blood cytopenias, and …

Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders
characterized by ineffective hematopoiesis with peripheral blood cytopenias, dysplastic cell …

There has been a remarkable explosion of knowledge into the molecular defects that
underlie the acute and chronic leukemias, leading to the introduction of targeted therapies …

Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis with
varying degrees of dysplasia and peripheral cytopenias. MDS are driven by structural …

Acute myeloid leukemia is characterized by arrested differentiation, and agents that
overcome this block are therapeutically useful, as shown by the efficacy of all-trans retinoic …

Opinion statement The treatment of myelodysplastic syndromes (MDS) begins with risk
stratification using a validated tool such as the International Prognostic Scoring System …

Myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) are aggressive
myeloid malignancies recognized as a distinct category owing to their unique combination of …

Acute myeloid leukemia (AML) is characterized by impaired differentiation and indefinite
proliferation of abnormal myeloid progenitors. Although differentiating agents were deemed …

Myelodysplastic syndrome (MDS) is a clonal hematopoietic neoplasm characterized by
bone marrow dysplasia, failure of hematopoiesis and variable risk of progression to acute …